Interview with Dr Zagozdzon on important management issues

Interview with Dr Zagozdzon, Poland on talking to patients about schizophrenia, quality of life and more.

Q. When you first tell a patient they have schizophrenia, do you tell them this is a lifelong condition?

A. We avoid using the term lifelong and usually postpones giving such information until asked or confronted. This is because, at the outset of managing a patient, it is unclear whether or not remission of psychosis is likely to be long-lasting or if the patient is at high risk of persistent symptoms.  The first visit is too early to make such a judgement, especially if there are problems with compliance.

Q. Having made a diagnosis of schizophrenia – do you tell patients at that point how long they are likely to need to be on medication?

A. Initially, the necessity for therapy is emphasised. Such therapy lasts 1 year or longer, depending on the course of the disease.

Q. What factors have a large contribution to the quality of life of a patient with schizophrenia?

A. The presence of psychotic symptoms impacts on a patient’s quality of life as do participating in social activities and being in paid employment.

Q. What methods do you employ to preserve or improve the quality of life of your patients with schizophrenia?

A. We take a holistic approach to patient management. We not only prescribe the most suitable therapy but we work with psychologists to get to know and understand our patients.

Q. Do you think of schizophrenia as a neurodevelopmental disorder or as a neurodegenerative disease?

A. Neither. Schizophrenia is a heterogeneous disease and looking at it from either perspective doesn’t help us as psychiatrists to choose the most appropriate therapies.  More needs to be known about the role that a history of trauma or genetics plays and we really don’t know how neurodevelopmental disorders are brought about.

Q. What proportion of patients with schizophrenia have the potential to achieve improvements in relationships?

A.  About 30% of patients can improve their relationships.

 

The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente agli Operatori Sanitari (medici e farmacisti). I contenuti di questo sito sono prodotti da un team di Operatori Sanitari il cui obiettivo è presentare le ultime novità in ambito psichiatrico e neurologico, attraverso interviste, registrazioni audio/video di seminari con opinion leader, report e sintesi di congressi sia internazionali che nazionali. Per poter accedere al sito è quindi necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Operatore Sanitario.
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country